KB Home, Lennar upgraded at RBC Capital on valuation, balanced risk/reward
RBC Capital Markets raised its recommendation on KB Home (NYSE:KBH) and Lennar (NYSE:LEN), considering the homebuilders' ...
RBC Capital Raises Xometry, Inc. (XMTR) Price Target: AI Innovation and Software Growth Drive Optimism for 2025
In the last two years, it’s happened for the fifth time. The S&P 500 was up 26% in 2023 and 25% in 2024, for the best ...
Hosted on MSN12h
RBC Capital Upgrades Bank of Montreal (BMO)
Fintel reports that on January 9, 2025, RBC Capital upgraded their outlook for Bank of Montreal (NYSE:BMO) from Sector ...
RBC Capital Remains a Buy on Exelixis (EXEL)
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) on January 7 and set a price target of $38.00.
Fed is 'done' cutting rates, strategist cites Q1 trends, jobs data
Blake Gwinn, the head of US Rates Strategy at RBC Capital Markets, joins Yahoo Finance's Morning Brief to explain why the ...
BBVA Sabadell Bid Tweak Stems From ‘Sloppy’ Draft, RBC Says
A small change in BBVA’s takeover offer for Banco Sabadell SA announced Thursday seems to be a correction of a previous ...
Lennar upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Lennar (LEN) to Sector Perform from Underperform with an unchanged price target of $130. The upgrade is valuation-based ...
Financial Services Roundup: Market Talk
Find insight on BBVA, Australia’s banks and more in the latest Market Talks covering Financial Services.
Hot jobs report cements a Fed rate hold this month — and possibly the foreseeable future
A hot jobs report makes it even more likely the Federal Reserve won’t cut rates at its next meeting in January — or for the foreseeable future.
Apellis stock drops on Astellas drug update
Investing.com -- Shares of Apellis Pharmaceuticals (NASDAQ: APLS) fell 8.9% in premarket trading following news that the FDA accepted a revised supplemental application from competitor Astellas Pharma ...